Can a new pill quiet stubborn chronic hives?

NCT ID NCT07764003

Not yet recruiting Disease control Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase II trial tests whether an experimental oral drug called TLL-018 can reduce itching and hives in adults with moderate-to-severe chronic spontaneous urticaria (CSU) that hasn't responded to standard antihistamines. Participants will take either a low or high dose of TLL-018 or a placebo daily for 12 weeks, while keeping a symptom diary and attending clinic visits every four weeks. The study compares changes in itch and hive severity scores to see which dose works best and how safe the drug is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TLL-018 tablets taken by mouth
What this could lead to: If successful, TLL-018 could offer a new treatment option for people with chronic hives that don't improve with standard antihistamines, potentially reducing itch and hives.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The drug may cause side effects or may not work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA (CSU) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA (CSU)

More trials for these conditions

Other studies related to the condition(s) this trial covers.